Drug intelligence / Profile preview

Tumor neoantigen vaccine (Henan Cancer Hospital)

Development stage: Unknown
Lead developer: Henan Cancer Hospital
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

A personalized therapeutic cancer vaccine developed by Henan Cancer Hospital for the treatment of advanced cancers. The vaccine is designed by identifying patient-specific somatic mutations through genome sequencing to select 'neoantigens'—proteins present only in tumor cells and not in healthy tissue. By customizing the vaccine to each patient's unique tumor profile, it aims to stimulate a robust and highly specific T-cell mediated anti-tumor immune response to eliminate cancer cells that have become resistant to standard therapies.

Other names: Personalized neoantigen vaccineTumor neoantigen vaccine

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on Tumor neoantigen vaccine (Henan Cancer Hospital).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor neoantigen vaccine (Henan Cancer Hospital).

Explore the full profile